Xspray Pharma Submits XS003 To FDA; Review Expected Within 60 Days
ReutersAug 19, 2025 4:31 PM
Aug 19 (Reuters) - XSpray Pharma AB (publ) XSPRAY.ST:
XSPRAY PHARMA SUBMITS XS003 TO THE FDA – THE COMPANY’S SECOND PRODUCT CANDIDATE FROM THE HYNAP PLATFORM
XSPRAY PHARMA AB (PUBL) - FDA REVIEW OF XS003 EXPECTED WITHIN 60 DAYS
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
[Crypto IPO] Figure Technology Follows Circle and Bullish with Nasdaq Listing Plans
On August 18, U.S.-based blockchain lending firm Figure Technology Solutions Inc. publicly announced it has filed a Form S-1 registration statement with the U.S. Securities and Exchange Commission (SEC), signaling its intent to go public on the Nasdaq Global Market under the ticker symbol FIGR.TradingKey
12 hours ago
Japan July CPI Preview: With Inflation Cooling, Will the Yen Still Rise?
TradingKey - Japan is set to release July inflation data on 22 August 2025. Market consensus predicts that the national Consumer Price Index (CPI) excluding fresh food will see its year-on-year increase slow from 3.3% in June to 3%. While forecasts for headline CPI and CPI excluding food and...TradingKey
15 hours ago
Powell's Jackson Hole Speech: For U.S. Stocks, Hawk or Dove Signal Could Be a Lose-Lose?
TradingKey - As U.S. inflation and labor market data show signs of rebalancing, Treasury traders and Wall Street banks have largely priced in a rate cut at the September FOMC meeting — the first of 2025. Yet both a more dovish-than-expected tone and a potential surprise hawkish signal from Fed ChairTradingKey
Mon, Aug 18
Eurozone Q2 GDP Commentary: Will the Euro's Upward Momentum Persist?
TradingKey - On 14 August 2025, Eurostat published Q2 GDP figures, revealing a drop in the Eurozone's quarter-on-quarter growth from 0.6% in the first quarter to 0.1%. Consequently, annual growth eased from 1.5% to 1.4%. The slowdown primarily stems from the diminishing boost from European...TradingKey
Mon, Aug 18
Bridgewater Associates Q2 2025 13F Analysis: Founder Ray Dalio’s Final Act
TradingKey - Bridgewater Associates, the world’s largest hedge fund and renowned for its macroeconomic analysis, continues to command market respect with its “risk parity” strategy and precise economic cycle timing.TradingKey
Thu, Aug 14
